Overview


According to FutureWise analysis the market for Pharmaceuticals Lipids in 2023 is US$ 4.93 billion, and is expected to reach US$ 7.41 billion by 2031 at a CAGR of 5.20%.

A lipid is a group of organic compounds that are present in a variety of organisms and animals, as well as plants. In addition to waxes, fats, sterols, and fat-soluble nutrients, they contain natural molecules. Mostly, they are used as excipients in the manufacture of drugs. Animals, plants, and microorganisms contain lipids, which are organic compounds. Fat-soluble vitamins, waxes, sterols, and waxes are some of these components. Lipids are capable of performing a variety of functions. Additionally, they are known to be low in toxicity. Lipids are capable of delivering drugs effectively because of these qualities. Therefore, they are increasingly used as excipients in the production of drugs. The pharmaceutical lipids market is fairly fragmented. Pharmaceutical lipids market is highly competitive due to the presence of many global and local players. The vendors in this market use a variety of strategies in order to gain a prominent position. Pharmaceutical technology considers lipids and polymers to be pillar excipients for the fabrication of most dosage forms, regardless of the route of administration. In addition to serving as support vehicles, they also serve as release rate modifiers, stabilizers, solubilizers, permeation enhancers, and transfection agents. When highly purified and refined to meet pharmaceutical specifications, several lipids are used as fillers, binders, lubricants, solubilizers, emulsifiers, and emollients in a wide range of delivery forms, including tablets, capsules, suppositories, emulsions (enteral/parenteral), ointments, creams, and lotions. The term lipid can be used to describe a group of organic compounds found in plants, animals, and microorganisms. Among them are sterols, waxes, fats, and fat-soluble vitamins. Lipids are capable of performing a variety of activities. Additionally, they are known to be low in toxicity. Lipids help deliver drugs effectively because of these qualities. In order to meet this demand, they are increasingly used as excipients in pharmaceutical production. The global pharmaceutical lipids market is growing due to this factor.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Pharmaceuticals Lipids Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Pharmaceuticals Lipids Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • ABITEC Corporation (ABF Ingredients)
  • BASF SE
  • Croda International Plc
  • CordenPharma
  • NOF (Nippon Oil and Fats) Corporation
  • Lipoid GmbH
  • Nippon Fine Chemical Co. Ltd.
  • Dishman Group
  • Gattefossé
  • IOI Oleo GmbH
  • Stepan Company
  • Evonik Industries AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Triglycerides
  • Phospholipids
  • Sphingolipids
  • Cholesterol
  • Fatty Acids
  • Others

By Source

  • Synthetic
  • Semi-synthetic
  • Natural

By Form

  • Liquid
  • Semi-solid
  • Solid

By Application

  • Conventional Lipid-based Drug Delivery Systems
  • Self-Emulsifying Drug Delivery Systems
  • Self-Microemulsifying Drug Delivery Systems
  • Liposomes
  • Solid Lipid Nanoparticles
  • Nanostructured Lipid Carriers
  • Others

By Route of Administration

  • Oral
    • Tablet
    • Solution
  • Parenteral
    • Intravenous
    • Intramuscular (Vaccines)
  • Topical

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Pharmaceuticals Lipids Market By Product, By Source, By Form, By Application, By Route of Administration and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Pharmaceuticals Lipids Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Pharmaceuticals Lipids Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Pharmaceuticals Lipids Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Pharmaceuticals Lipids Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Triglycerides
        2. Phospholipids
        3. Sphingolipids
        4. Cholesterol
        5. Fatty Acids
        6. Others

  • 8.   Pharmaceuticals Lipids Market, By Source Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Synthetic
        2. Semi-synthetic
        3. Natural

  • 9.   Pharmaceuticals Lipids Market, By Form Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Liquid
        2. Semi-solid
        3. Solid

  • 10.   Pharmaceuticals Lipids Market, By Applications Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Conventional Lipid-based Drug Delivery Systems
        2. Self-Emulsifying Drug Delivery Systems
        3. Self-Microemulsifying Drug Delivery Systems
        4. Liposomes
        5. Solid Lipid Nanoparticles
        6. Nanostructured Lipid Carriers
        7. Others

  • 11.   Pharmaceuticals Lipids Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
         1.1. Tablet
         1.2. Solution
        2. Parenteral
         2.1. Intravenous
         2.2. Intramuscular (Vaccines)
        3. Topical

  • 12.   North America Pharmaceuticals Lipids Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Pharmaceuticals Lipids Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Pharmaceuticals Lipids Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Pharmaceuticals Lipids Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Pharmaceuticals Lipids Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. ABITEC Corporation (ABF Ingredients)
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. BASF SE
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Croda International Plc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. CordenPharma
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. NOF (Nippon Oil Fats) Corporation
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Lipoid GmbH
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Nippon Fine Chemical Co. Ltd.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Dishman Group
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Gattefossé
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. IOI Oleo GmbH
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Stepan Company
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Evonik Industries AG
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients